Sarah Rutherford, M.D.
Weill Medical College of Cornell University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sarah Rutherford, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05994235 · Tazemetostat and Mosunetuzumab in Untreated Follicular LymphomaWeill Medical College of Cornell University · active not recruiting · Follicular Lymphoma · principal investigator
- Ph1NCT03036904 · Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell LymphomasWeill Medical College of Cornell University · completed · Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.